Search results for "bone"

showing 10 items of 2629 documents

Simple bone cyst : a case report

2021

Background Simple bone cysts (SBC) are intraosseous cysts devoid of an epithelial lining, asymptomatic and appearing in the jaw. In general, SBCs are discovered incidentally and tooth displacement or pathological fractures are very unusual. Material and methods This study reports a 16 years old man that presented an asymtomatic radiolucent unilocular lesion in the right ascending ramus. Differencial diagnosis included odontogenic keratocyst and dentigerous cyst. One surgical intervention was performed and consisted in the curettage of the bone walls. The lesion and some small samples of the bone wall were sent for the anatomopathological study. Results The anatomopathological exam confirmed…

medicine.medical_specialtyTeethmedicine.medical_treatmentCase ReportJawsQuistosLesion03 medical and health sciences0302 clinical medicineOral surgerymedicineDentsCystKeratocystBone regenerationGeneral DentistryTraumatic bone cystUNESCO:CIENCIAS MÉDICASOral Medicine and PathologyCirurgia oralMaxil·larsbusiness.industrySimple Bone Cyst030206 dentistrymedicine.diseaseCurettageDentigerous cystSurgeryCysts (Pathology)030220 oncology & carcinogenesismedicine.symptombusiness
researchProduct

Transplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Mod…

2010

The aim of this study is to assess the long-term effect of mesenchymal stem cells (MSC) transplantation in a rat model of chronic myocardial infarction (MI) in comparison with the effect of bone marrow mononuclear cells (BM-MNC) transplant. Five weeks after induction of MI, rats were allocated to receive intramyocardial injection of 106 GFP-expressing cells (BM-MNC or MSC) or medium as control. Heart function (echocardiography and 18F-FDG-microPET) and histological studies were performed 3 months after transplantation and cell fate was analyzed along the experiment (1 and 2 weeks and 1 and 3 months). The main findings of this study were that both BM-derived populations, BM-MNC and MSC, ind…

medicine.medical_specialtyTime FactorsAngiogenesisMyocardial InfarctionBiomedical Engineeringlcsh:Medicine030204 cardiovascular system & hematologyMesenchymal Stem Cell TransplantationPeripheral blood mononuclear cellTimeRats Sprague-DawleyAndrology03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsRegenerationChronic myocardial infarctionCells CulturedCardiac remodelingBone Marrow Transplantation030304 developmental biologyStem cell transplantation for articular cartilage repair0303 health sciencesTransplantationBone marrow stem cellsVentricular Remodelingbusiness.industryMyocardiumlcsh:RMesenchymal stem cellBone Marrow Stem CellCell BiologyRatsEndothelial stem cellTransplantationDisease Models AnimalTreatment Outcomemedicine.anatomical_structureChronic DiseaseCardiologyFemaleAngiogenesisBone marrowbusinessCell Transplantation
researchProduct

Influence of long-term postmenopausal hormone-replacement therapy on estimated structural bone strength: A study in discordant monozygotic twins

2010

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft,…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentDentistryMonozygotic twin030209 endocrinology & metabolismBone and Bones03 medical and health sciences0302 clinical medicineBone strengthBone DensitymedicineHumansPostmenopausal Hormone Replacement TherapyOrthopedics and Sports Medicineta315Aged030304 developmental biologyBone mineral0303 health sciencesPostmenopausal womenAnthropometrybusiness.industryEstrogen Replacement Therapyta3141Hormone replacement therapy (menopause)Organ SizeTwins Monozygoticta3142Middle AgedHormonesConfidence intervalSurgerymedicine.anatomical_structureBody CompositionFemaleCortical boneDiaphysesSelf ReportbusinessJournal of Bone and Mineral Research
researchProduct

Effect of CYP1A1 Gene Polymorphisms on Estrogen Metabolism and Bone Density

2004

UNLABELLED: In this study, we evaluated the effect of polymorphisms of the CYP1A1 gene, linked to hormone-related cancers, on estrogen metabolism and BMD. We found that variants carrying the A allele (CA and AA) for the C4887A polymorphism have a significantly higher degree of estrogen catabolism and lower femoral BMD. INTRODUCTION: Polymorphisms of the CYP1A1 gene, one of the key enzymes that metabolize estrogen, have been linked with hormone-related cancers. We investigated the impact of these polymorphisms on estrogen metabolism and BMD, which is another hormone-dependent health issue. MATERIALS AND METHODS: One hundred seventy postmenopausal women (mean age, 63.5 +/- 0.6 years) particip…

medicine.medical_specialtyTime FactorsGenotypeBone densitymedicine.drug_classEndocrinology Diabetes and MetabolismOsteoporosisRadioimmunoassayBiologyArticleCollagen Type IBone resorptionImmunoenzyme TechniquesAbsorptiometry PhotonBone DensityRisk FactorsInternal medicinehormones and receptorGenotypeCytochrome P-450 CYP1A1medicineHumansosteoporosiOrthopedics and Sports MedicineFemurBone ResorptionAllelesAgedPolymorphism GeneticEstradiolgenetic researchEstrogensMiddle Agedmedicine.diseaseGenotype frequencyPostmenopauseMenopauseEndocrinologyEstrogenepidemiologyFemaleCollagenGene polymorphismMenopausePeptidesPolymorphism Restriction Fragment LengthJournal of Bone and Mineral Research
researchProduct

Duration of breastfeeding as a risk factor for vertebral fractures

2014

Abstract Purpose Among the risk factors for osteoporosis and fractures, gynecological history (fertile period, parity and breastfeeding) play an important part. Changes in calcium metabolism to enable an adequate mineral transfer to the milk have a prominent role in bone loss during breastfeeding. Data on the influence of breastfeeding in postmenopausal osteoporosis are inconsistent. The aim of the present study was to identify any association between duration of breastfeeding and vertebral fractures in postmenopausal women. Methods All patients underwent the following tests: bone mineral density measurements of the lumbar spine (L1–L4) and the total and femoral neck using dual-energy X-ray…

medicine.medical_specialtyTime FactorsHistologyPhysiologybreastfeedingEndocrinology Diabetes and MetabolismOsteoporosisBreastfeedingcalcium metabolismPregnancyRisk FactorsLactationConfidence IntervalsOdds RatiomedicineHumansvertebral fracturesRisk factorFemoral neckBone mineralPregnancybusiness.industryObstetricsrisk factors for osteoporosiMiddle Agedmedicine.diseaseSurgeryMenopauseBreast Feedingmedicine.anatomical_structureSpinal FracturesFemalebusiness
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence-a multi-centre study

2011

Abstract Introduction Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy. Patients and methods This current study assessed 470 cases of BRONJ diagnosed between 2004 and 2008 at eleven different European clinical centres and has resulted in the …

medicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.medical_treatmentOral Surgical ProceduresOsteoporosisAdministration OralSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansMedical historyAdverse effectBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryContraindicationsOsteonecrosisBisphosphonatemedicine.diseaseSurgeryZoledronic acidOtorhinolaryngologyCohortOral and maxillofacial surgeryOsteoporosisSurgeryOral Surgeryosteoporosis bisphosphonates ostenecrosis jawsOsteonecrosis of the jawbusinessJaw Diseasesmedicine.drug
researchProduct

Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function

2013

After entering the blood, bisphosphonates are immediately bound to bone or excreted unchanged by the kidney. During renal excretion about 0.5% of administrated dosage remains in kidney tissue. The renal tissue level of bisphosphonates (RTL) decreases over time and remains at about 0.15% after 3weeks, but the influence of renal insufficiency (RI) is unclear.We investigated the influence of mild to moderate RI on RTL of ibandronate (IBD). First a method for determination of RTL was implemented and validated. We measured RTL in rats with normal renal function (SHAM) and after unilateral nephrectomy (UNX). In each case one SHAM and one UNX groups received one or alternatively 9 times every 3wee…

medicine.medical_specialtyTime FactorsUrologyKidneyToxicologySeverity of Illness IndexImpaired renal functionNormal renal functionmedicineAnimalsTissue DistributionRenal InsufficiencyRats WistarIbandronic AcidPharmacologyKidneyBone Density Conservation AgentsDiphosphonatesbusiness.industryRenal tissueUnilateral nephrectomyRatsSurgeryDisease Models Animalmedicine.anatomical_structureRenal physiologyFemalebusinessHalf-LifeJournal of Pharmacological and Toxicological Methods
researchProduct

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner – A quantitative in vitro gene expression analy…

2010

Bisphosphonates are widely used in the clinical treatment of bone diseases with increased bone resorption. In terms of side effects, they are known to be associated with osteonecrosis of the jaw (BONJ). There are two groups of bisphosphonates: the nitrogen-containing bisphosphonates, e.g. zoledronate and ibandronate, and the non-nitrogen-containing bisphosphonates, e.g. clodronate. Their impact on bone metabolism seems to differ. The objective of this study was to compare the osteogenic differentiation potency of these two pharmacologic groups. Human osteoblasts were stimulated with zoledronate and ibandronate at concentrations of 5×10(-5) M, 5×10(-6) M and 5×10(-7) M over the experimental …

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentOsteocalcinCell Culture TechniquesCore Binding Factor Alpha 1 SubunitZoledronic AcidIbandronic acidBone remodelingInternal medicineHumansMedicineIbandronic AcidHomeodomain ProteinsMSX1 Transcription FactorOsteoblastsBone Density Conservation AgentsDiphosphonatesDose-Response Relationship DrugbiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryImidazolesCell DifferentiationOsteoblastDLX5BisphosphonateRUNX2Zoledronic acidmedicine.anatomical_structureEndocrinologyGene Expression RegulationOtorhinolaryngologyOsteocalcinbiology.proteinSurgeryBone RemodelingClodronic AcidOral SurgerybusinessBiomarkersTranscription Factorsmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Multiple brown tumours of tertiary hyperparathyroidism in a renal transplant recipient: : a case report

2010

Tertiary Hyperparathyroidism (HPT) is an uncommon condition that affects patients with secondary HPT after a successful kidney transplant. Bone alterations are the main consequences of this endocrine condition, including the development of an osteolytic lesion called brown tumour. This paper reports an unusual case of multiple brown tumours located in the maxilla and mandible in a 58-year-old renal transplant recipient, with tertiary HPT. Incisional biopsies were performed and, in both samples, the histopathological diagnoses were giant cell lesions. Due to these diagnoses, the medical history of chronic renal failure, and high levels of serum calcium and PTH, lesions were diagnosed as mult…

medicine.medical_specialtyTotal parathyroidectomyBone NeoplasmsTertiary hyperparathyroidismOrgan transplantationNeoplasms Multiple PrimarymedicineEndocrine systemHumansMedical historyGeneral Dentistrybusiness.industryHyperparathyroidismMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Jaw NeoplasmsKidney TransplantationSurgeryOtorhinolaryngologyRenal transplantGiant cellMaxillaUNESCO::CIENCIAS MÉDICASSurgeryFemalebusiness
researchProduct